Sign in

You're signed outSign in or to get full access.

AT

Aerovate Therapeutics, Inc. (AVTE)·Q3 2023 Earnings Summary

Executive Summary

  • Q3 2023 delivered expected pre‑commercial financials: net loss of $19.6M and diluted EPS of $(0.71), driven by R&D of $16.9M and G&A of $4.5M as IMPAHCT trial execution ramped . Cash, cash equivalents and AFS securities were $135.2M; management reiterated funding runway into 2026 .
  • Clinical execution advanced: >125 sites activated in >20 countries; topline Phase 2b data guided for Q2 2024 . Within the quarter’s update cadence, Aerovate later announced Phase 2b enrollment completion (202 patients) and first Phase 3 patient enrolled—key value inflection on path to Phase 2b readout in Q2 2024 .
  • IP strengthened: USPTO issued Patent 11,806,349, bringing total issued patents to five; global prosecution continues .
  • Estimate comparisons: S&P Global consensus EPS/revenue for AVTE were unavailable; beats/misses vs Street cannot be assessed this quarter (see Estimates Context).

What Went Well and What Went Wrong

What Went Well

  • IMPAHCT execution milestones: “The completion of enrollment in the Phase 2b portion of the trial marks an exciting milestone…” and immediate Phase 3 initiation under the adaptive design .
  • Funding runway improved and then maintained: Runway extended to 2026 by Q2 (via ATM proceeds) and reaffirmed in Q3, supporting Phase 2b readout and Phase 3 enrollment .
  • Portfolio/IP: issuance of USPTO Patent 11,806,349; total issued patents now five, enhancing protection around AV‑101 .

What Went Wrong

  • Operating losses widened YoY as clinical spending scaled: net loss rose to $19.6M in Q3 (from $13.6M in Q3’22) with R&D up $6.1M YoY on headcount, CMO and trial costs .
  • Enrollment pace previously slower than expected due to post‑COVID site staffing, necessitating extended activation efforts and timelines (management acknowledged this in Q1 commentary) .
  • No product revenue (pre‑commercial), and cost base continues to rise with Phase 2b/3 execution; quarterly cash stepped down from $150.1M in Q2 to $135.2M in Q3 on operating use .

Financial Results

MetricQ1 2023Q2 2023Q3 2023
Revenue ($USD Millions)$0.0 $0.0 $0.0
R&D Expenses ($USD Millions)$13.488 $16.034 $16.884
G&A Expenses ($USD Millions)$4.151 $4.302 $4.484
Total Operating Expenses ($USD Millions)$17.639 $20.336 $21.368
Other Income ($USD Millions)$1.119 $1.311 $1.805
Net Loss ($USD Millions)$16.520 $19.025 $19.563
Diluted EPS ($USD)$(0.67) $(0.76) $(0.71)
Weighted Avg Shares (basic & diluted)24,777,847 25,166,505 27,640,542
Cash, Cash Equivalents & AFS ($USD Millions)$118.929 $150.096 $135.199

Segment breakdown: N/A (single asset, pre‑commercial company) .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Topline Phase 2b data timingQ3 2023Q2 2024 (from Q2 update) Q2 2024 Maintained
Cash runwayQ3 2023Into 2026 (from Q2) Into 2026 Maintained
Cash runwayQ2 20232H 2025 (from Q1) Into 2026 Raised
Sites activatedQ3 2023>110 in >20 countries (Q2) >125 in >20 countries Increased
Enrollment statusQ3 2023Ongoing Phase 2b enrollment Phase 2b enrollment completed (202 patients); first Phase 3 patient enrolled (Nov 20 update) Achieved milestone

Earnings Call Themes & Trends

TopicPrevious Mentions (Q-2 and Q-1)Current Period (Q3 2023)Trend
Trial enrollment & executionQ1: >100 sites; pace slower than expected due to post‑COVID; topline guided Q2 2024 . Q2: >110 sites; activation/enrollment continued; topline Q2 2024 .Q3: >125 sites; topline Q2 2024 reiterated . Post‑Q3 update: Phase 2b enrollment completed (202 patients) and Phase 3 initiated .Improving execution; key milestone achieved
Cash runway & financingQ1: funded into 2H 2025 . Q2: extended into 2026, aided by ATM proceeds .Q3: runway into 2026 reaffirmed; $135.2M cash & AFS at 9/30 .Strengthened then maintained
IP/defensibility—USPTO Patent 11,806,349 issued; total five issued patents .Expanding IP
Regulatory/operational risksPost‑COVID staffing/site activation challenges impacting timelines noted in MD&A/Risk Factors .Ongoing vigilance; adaptive design supports continuity .Headwinds gradually easing
R&D expense trajectoryQ1 R&D $13.5M; Q2 $16.0M .Q3 $16.9M as trial scales .Rising with Phase 2b/3 progress

Management Commentary

  • “One of our priorities over the past year was opening clinical trial sites globally… Patient enrollment has been slower than expected, in part related to post‑COVID factors… we project topline Phase 2b data in the second quarter of 2024.” — Tim Noyes, CEO (Q1 press release) .
  • “The completion of enrollment in the Phase 2b portion of the trial marks an exciting milestone… we were also able to rapidly enroll our first patient in the Phase 3 portion…” — Tim Noyes, CEO (Nov 20 press release) .

Q&A Highlights

  • A formal Q3 2023 earnings call transcript was not available in our document corpus or via public transcript aggregators; MarketBeat lists an 8:00 AM ET call on Nov 13, 2023 but no transcript content was accessible .
  • As a result, no Q&A themes or guidance clarifications could be extracted or verified for Q3.

Estimates Context

  • Wall Street consensus (S&P Global Capital IQ) for AVTE EPS and revenue was unavailable due to a mapping issue; therefore, we cannot assess beats/misses versus consensus this quarter. If/when SPGI adds AVTE mapping, we will incorporate consensus comparisons in future updates.

Key Takeaways for Investors

  • Phase 2b topline remains the critical catalyst in Q2 2024; completion of Phase 2b enrollment (202 patients) and Phase 3 initiation de‑risk execution timing .
  • Funding runway into 2026 provides capital continuity across Phase 2b readout and ongoing Phase 3 enrollment, reducing near‑term financing overhang .
  • R&D spend is trending higher with trial scale; expect continued operating losses until clinical readouts and eventual commercialization—this is consistent with a single‑